Openbookopenbook
Equity
StockUS listing USBLFSNASDAQHealthcareProfitless Growth

BioLife Solutions Inc(BLFS) Stock Analysis | Healthcare

USD --+0.00%
Reward51Moderate
Risk59Medium-High
75%Data
Strong 54% profit margin · Revenue growing 22% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 1.89Bn
Reward Ratingⓘ51 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ59 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BLFS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is BioLife Solutions Inc?

develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.

AI Brief Pro

The brief on BioLife Solutions Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is BioLife Solutions Inc?

develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.89B, and a P/E ratio of 39.0x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (51)

Similar stocks to compare

A short list of Medical Instruments & Supplies names that are close enough in size to make side-by-side comparison useful.

LMATSmall Cap / 1.8B market cap
LeMaitre Vascular Inc
Compare
AGLFFSmall Cap / 1.7B market cap
ANGELALIGN TECHNOLOGY INC
Compare
XRAYSmall Cap / 1.7B market cap
Dentsply Sirona Inc
Compare
Company Information
SectorHealthcare
IndustryMedical Instruments & Supplies
Market Cap1.89B
P/E Ratio39
Dividend YieldN/A
Beta1.824
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
899,641 shares
$2.0M
0
9-12months
127,802 shares
$196k
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.